MANAGEMENT
EAMONN P. HOBBS - Chief Executive Officer, President and Director
Mr. Hobbs has been a Director since October 2008 and was appointed President and CEO in July 2009. From 1988 until earlier this year, Mr. Hobbs was President and CEO of AngioDynamics, Inc. (Nasdaq: ANGO). As a co-founder, he built AngioDynamics into a leading medical technology company with an international market presence and a highly diverse product line. Throughout his tenure at AngioDynamics, Mr. Hobbs led the Company's efforts in marketing, strategic planning, product development, and general management. In 2004, AngioDynamics was spun off from E-Z-EM, Inc., a healthcare company focused on diagnostic technologies, where Mr. Hobbs served as Senior Vice-President since 1988. Before his involvement with these companies, Mr. Hobbs was the Director of Marketing and Product Development at NAMIC, Founder, President and CEO of Hobbs Medical, Inc., and a Product Development Engineer at Cook Incorporated. Mr. Hobbs has over 25 years experience in the interventional radiology, interventional cardiology and gastroenterology medical device industries. He received a Bachelor of Science in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts in Lowell in 1980. Mr. Hobbs is Vice Chairman of the Board of Directors of the Medical Device Manufacturers Association (MDMA)
DAVID MCDONALD - Chief Financial Officer
McDonald founded Minneapolis-based Cornerstone Healthcare Advisors LLC in April 2005, which he led until joining AngioDynamics in July 2008. At Cornerstone he provided advisory and consulting services to emerging medical technology companies and their financial sponsors.
Prior to 2005, McDonald was a Managing Director and leader of Medical Technology Investment Banking at RBC Capital Markets where he developed senior and Board level relationships with leading private, public and venture capital firms in the medical device and diagnostics industries. While at RBC and Cornerstone, Mr. McDonald advised on more than 50 banking deals.
Before his involvement with these companies, Mr. McDonald was a Senior Vice President and Equity Portfolio Manager at Investment Advisers, Inc. as well as a research analyst covering the healthcare industry for more than a dozen years. He received a Bachelor of Arts Degree in Economics from St. Olaf College in Northfield, Minnesota in 1982
KRISHNA KANDARPA, M.D., PH.D. - Executive Vice President, Research and Development and Chief Medical Officer
Dr. Kandarpa has been Executive Vice President, Research and Development and Chief Medical Officer since October 2009. Dr. Kandarpa earned his M.D. from the University of Miami Miller School of Medicine, Miami, FL. He completed his residency and fellowship in Interventional Radiology at the Brigham & Women's Hospital, Harvard Medical School in Boston, MA. Dr. Kandarpa earned his Ph.D. in Engineering Science & Mechanics from Penn State University and a B.S. in Aerospace & Mechanical Engineering from Washington University (St. Louis). Prior to joining Delcath, since 2002, he was a tenured Professor and Chair of the Department of Radiology at the University of Massachusetts Medical School (UMMS) and Radiologist-in-Chief at the University of Massachusetts Memorial Medical Center. Prior to 2002, he was at the Weill Medical College of Cornell University, where he was a Professor of Radiology and Chief of Service and Director of the Division of Cardiovascular & Interventional Radiology at The New York Presbyterian Hospital (Cornell), NY, NY. He was also a faculty member at the Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology from 1987 to 1998. Prior to attending medical school, Dr. Kandarpa was a Research and Development Engineer at Duracell International Laboratory for Physical Science. Dr. Kandarpa is past-President (1997-2001) and past-Chair (2001-2002) of the Research and Education Foundation of the Society of Interventional Radiology (SIR). He completed his final term on the Board of Directors of the Academy of Radiology Research in 2007. Dr. Kandarpa has authored over 50 original peer-reviewed scientific publications, including book chapters and invited articles, and is the author/editor of several specialized books, including The Handbook of Interventional Radiologic Procedures, and a new textbook entitled Peripheral Vascular Interventions (2008). Dr. Kandarpa is listed among Best Doctors in America and America’s Top Doctors.
AGUSTIN GAGO - Executive Vice President, Global Sales and Marketing
Mr. Gago has been the Executive Vice President for Global Sales and Marketing since November 2009. Mr. Gago has over 25 years experience in the medical device, diagnostic and pharmaceutical industries, with a focus on the medical specialties of oncology, interventional radiology, radiology, surgery, gastroenterology and speech pathology.
Before joining Delcath , Mr. Gago was with AngioDynamics, Inc. as Vice President of International Oncology/Surgery Sales. Prior to AngioDynamics, Mr. Gago spent over 20 years with E-Z-EM, Inc., where he specialized in developing and building distributor and partner relationships in Asia, Europe, Africa and South America as Vice President / Global GI Business Unit, Vice President of International Sales, Vice President of International Operations and as Director of Global Logistics.
Mr. Gago holds a BS in Business Management from Hofstra University and Diplomas in International Business and Import/ Export Practices from a number of overseas universities.
JOHN PURPURA - Executive Vice President for Regulatory Affairs and Quality Assurance
Mr. Purpura has been the Executive Vice President for Regulatory Affairs and Quality Assurance since November 2009. Mr. Purpura was most recently with Bracco/E-Z-EM as Vice President and then Executive Director of International Regulatory Affairs from 2007 to 2008, and Head of Regulatory Affairs for North America and Latin America from 2008 to October 2009. Prior to E-Z-EM, Mr. Purpura had an 11-year career with Sanofi-Aventis in progressively more senior regulatory CMC responsibilities, ultimately serving as Associate Vice President for Regulatory CMC from 2005 to 2007. Prior to Sanofi, Mr. Purpura held various quality and regulatory management roles with Eon Labs Manufacturing, Luitpold Pharmaceuticals and Bolar Pharmaceuticals from 1985 to 1995. He earned a MS in Management & Policy and BS degrees in Chemistry and Biology at the State University of New York at Stony Brook.
JASON A. RIFKIN - Senior Vice President Clinical Operations
Mr. Rifkin has been Senior Vice President of Clinical Operations since December 2008 and before that was Vice President of Business Development starting in June 2007. Prior to joining Delcath, Jason practiced law at Fox Rothschild LLP, where he was an Associate in the Corporate Department - Pharmaceuticals and Biotechnology Group. There, Mr. Rifkin worked extensively on intellectual property matters, including domestic and international patent applications, and regulatory and licensing issues. Prior to that, Mr. Rifkin practiced at a boutique litigation firm in New York City, where he served as trial and appellate counsel in a wide array of cases in both federal and state courts. Mr. Rifkin holds a B.A. from the University of Pennsylvania, a J.D. from Northeastern University School of Law and an M.B. in Biotechnology from the University of Pennsylvania, School of Engineering and Applied Sciences.
ARMAND "CHUCK" FRIGON - Vice President for Operations
Mr. Frigon has been Vice President for Operations since November 2009. He has been general manager of Sterigenics International since 2007. Prior to Sterigenics, Mr. Frigon was with Tyco Healthcare since 1988 as materials manager in its disposable medical device unit. He was Production and Inventory Control Manager and Senior Industrial Engineer at Mallinkrodt Anesthesia Products from 1983 to 1988 and Production Manager, Plant Engineering Manager, and Plant Industrial Engineer at CR Bard from 1979 to 1982. He earned a BA in Operations Management from Excelsior College.
BARBRA C. KECK - Controller
Mrs. Keck has been Controller since January 2009. Immediately prior to joining Delcath, she was a member of Deloitte & Touche's auditing practice. Mrs. Keck has spent much of her career working in the non-profit sector where she focused on creating strong partnerships with funding and advocacy groups. Mrs. Keck completed her undergraduate degree at the University of Dayton and her MBA in Accounting at Baruch College's Zicklin School of Business.
DIRECTORS
HAROLD S. KOPLEWICZ, M.D. - Chairman of the Board
Dr. Koplewicz has been a Director since September 2006 and was appointed Chairman in February 2007. He was appointed Chairman of the Board in February 2007. In May 2006, Dr. Koplewicz was appointed by then-New York Governor George Pataki to the position of Executive Director of the Nathan S. Kline Institute for Psychiatric Research, where he is the third person to hold this position since 1952. Dr. Koplewicz is also the Arnold and Debbie Simon Professor and Chairman of the Department of Child and Adolescent Psychiatry and Professor of Pediatrics and founder of the NYU Child Study Center at the New York University School of Medicine. He has served as a member of the National Board of Medical Examiners and as a commissioner of the New York State Commission on Youth, Crime and Violence and Reform of the Juvenile Justice System.
ROBERT B. LADD, CFA - Director
Mr. Ladd has been a director since October 2006. Since January 2003, Mr. Ladd has served as the founder and managing member of Laddcap Value Associates LLC, the general partner of Laddcap Value Partners LP, an investment management company. From 1988 to November 2002, Mr. Ladd served as a Managing Director of Neuberger Berman, an investment management company, where his responsibilities included serving as a portfolio manager for various high net worth clients and as a securities analyst. Mr. Ladd graduated from the University of Pennsylvania's Wharton School with a B.S. in Economics in 1980. He received his MBA from Northwestern University's Kellogg School of Management in 1983. Mr. Ladd has also earned a CFA designation.
RICHARD TANEY, JD - Director
Mr. Taney has been a Director since November 2006. Mr. Taney served as the Chief Executive Officer of Delcath from December 2006 and the President from April 2007 until July 2009. He is the founding member of T2 Capital Management, LLC, an investment management company. Prior to establishing his money management venture, he spent 20 years advising and managing assets for high net worth and institutional clients, at Salomon Brothers, Goldman Sachs and most recently as Managing Director of Banc of America Securities. Mr. Taney is also a founding partner of Sandpiper Capital Partners, an investment partnership that focuses on private equity investments and advisory work for privately held companies involved in a variety of emerging technologies. He earned his B.A. from Tufts University and his J.D. from Temple University School of Law.
LAURA A. PHILIPS, PH.D., MBA - Director
Dr. Philips has been a Director since May 2007. Dr. Philips currently serves as Chair of the Board of Directors of Planned Parenthood of New York City, and on the Board of Directors of Boyce Thompson Institute. From 2003 to 2006, she was Chief Operating Officer and Acting Chief Financial Officer of NexGenix Pharmaceuticals. Prior to that, she was Vice President, Program Management for the AMDeC Foundation. Dr. Philips worked at Corning Incorporated from 1997 to 2002, where she held several positions including Program Director of the Fuel Cells Division. From 1994 to 1996 Dr. Philips held various government positions in Washington, D.C., most recently in a Presidential appointment as Senior Policy Advisor to Secretary of Commerce Ronald Brown. Dr. Philips was on the faculty of Cornell University in the Department of Chemistry from 1987 to 1994 and was an NIH Post-Doctoral Fellow at the University of Chicago. She received a B.A. in Chemistry from Williams College, a Ph.D. in Physical Chemistry from the University of California Berkeley and an MBA with Distinction from Cornell University's Johnson School of Management.
ROGER G. STOLL, PH.D. - Director
Dr. Stoll has been a director since December 2008. From 2002 to 2008 he served as Chief Executive Officer and President of Cortex Pharmaceuticals, Inc., where he was appointed Executive Chairman in August 2008. From 2001 to 2002, he was a consultant to several east coast venture capital firms and startup ventures. From 1998 to 2001, he was Executive Vice President of Fresenius Medical Care-North America, in charge of the dialysis products division and the diagnostic systems business units, which included hemodialysis machines and dialysis filters equipment. From 1991 to 1998 he was Chief Executive of Ohmeda, a global leader in anesthesia pharmaceuticals and related operating room equipment and devices. He also served on the boards of directors of St. Jude Medical and the BOC Group, plc. From 1986 to 1991, Dr. Stoll held several executive management positions at Bayer, AG, including Executive Vice-President and General Manager for the worldwide Diagnostic Business Group. Prior to that, Dr. Stoll worked for American Hospital Supply Corp, where he rose from Director of Clinical Pharmacology to President of its American Critical Care Division. He began his pharmaceutical career at the Upjohn Company in 1972. Dr. Stoll obtained his BS in Pharmacy from Ferris State University, obtained a Ph.D. in Biopharmaceutics and Drug Metabolism at the University of Connecticut, and was a post-doctoral fellow for two years at the University of Michigan. Dr. Stoll also serves on the board of directors of Chelsea Therapeutics and School of Pharmacy Advisory Board of the University of Connecticut.
PAMELA R. CONTAG PH.D. - Director
Dr. Contag has been a director since December 2008. Dr. Contag founded in 2006 and currently is Chief Technology Officer of Cobalt Technologies, Inc., which engages in the development of biofuel production technologies. Prior to starting Cobalt, she founded Xenogen Corporation, which specializes in technology and services for preclinical drug development and testing, where she served as President and Director from 1995 to 2006. Xenogen, which went public in 2004, was acquired in 2006 by Caliper Life Sciences. Xenogen was listed as one of the "Top 25 Young Businesses" by Fortune Small Business and twice received the "R&D 100 Award." Dr. Contag was also recognized as one of the "Top 25 Women in Small Business" by Fortune magazine. Dr. Contag received her Ph.D. in Microbiology from the University of Minnesota Medical School and completed her postdoctoral training at Stanford University School of Medicine. Dr. Contag is a consulting Professor at the Stanford School of Medicine and is widely published in the field of non-invasive molecular and cellular imaging.
EAMONN P. HOBBS - Chief Executive Officer, President and Director